Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

1 source1 article First seen 17 hours ago Updated 17 hours ago China Truth score 34

Save Like Comments Compare coverage

Summary

SHANGHAI and HANGZHOU, China and BOSTON, Nov. 5, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core product,…

Description from Amherst Bee.

Who is covering this

Amherst Bee Not rated US 17 hours ago
Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis
SHANGHAI and HANGZHOU, China and BOSTON, Nov. 5, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for...

Comments

Comments need JavaScript.

Truth score

34/100Weakly supported

Independent outlets: 1
Source reliability: Not rated
Sides of the spectrum covering it: 0/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

No rated outlets yet

Left: 0
Centre: 0
Right: 0
Not rated: 1

How lean is counted

Source quality

Average reliability: Not rated
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

In this story

Lynk Pharmaceuticals Co Lynk Pharmaceuticals Drug Application

Filter the stories

Sources Ratings and details

Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

Summary

Who is covering this

Comments